Case Study: SunRISe Clinical Trial Patient Recruitment

A phase 2 clinical trial evaluating TAR-200 in combination with cetrelimab for muscle-invasive bladder cancer.

THE CLINICAL TRIAL
Bladder cancer is the tenth most common malignancy worldwide. Approximately 25 percent (%) of all new bladder cancer participants present with muscle invasive bladder cancer (MIBC) at the time of diagnosis, and roughly 50% will ultimately develop distant metastases. The SunRISe Clinical Trials was a suite of three clinical studies anti-tumor effects of TAR-200 – an intravesical drug delivery system – in combination with intravenous (IV) cetrelimab and IV cetrelimab alone.

THE PROJECT
Janssen and PRA Health Sciences set out to establish a global brand identity for the suite of SunRISe Studies and enlisted the patient recruitment team at Stark / Raving to deliver. The program encompassed four unique global clinical studies, each with specific criteria for both study participants and clinical teams. Our approach emphasized the significance of inclusivity, striving to represent a diverse patient population and providing accessible information across a range of materials to assist patient in their clinical trial journey.

KEY OUTCOMES

Saved 4% of their total SaaS spend in the first 3 months, and 16% in the first year working with Zylo
Revealed 30% overspend in budget
Saved 10 hours per week, allowing more focus on strategic work
75 contracts negotiated by Zylo in year one
Reduced number of applications by 10% while experiencing rapid growth

Clinical trial for bladder cancer patient recruitment branding

Operationalizing the creative process to successfully deliver a large-scale clinical study.

To guarantee prompt and precise delivery of patient and site-facing materials, the extensive scope and scale of this project required thorough upfront planning. Before initiating the development of creative concepts, our project management team partnered with the CRO to formulate a comprehensive plan that considered every aspect of material development, review cycles, IRB/EC approvals, translations, printing, and distribution. Setting up this process at the project’s outset ensured agreement on roles and responsibilities among all parties involved.

Clinical trial for bladder cancer patient recruitment project management

SunRISe Clinical Trial Study Content Development

Creating a brand identity system that could support multiple clinical studies.

Our primary focus was to develop a robust umbrella brand identity that could stand alone and adapt easily to encompass three different clinical studies. To achieve this, we concentrated on establishing a comprehensive set of brand standards that outlined how the visual identity would transform with the activation of each study. These standards encompassed all visual elements such as the logo, color, and photography, along with a defined messaging strategy for each individual study.

Patient-friendly content development focused on health literacy.

The SunRISe studies shared a common trait – a complex study design that presented daunting requirements to the study participants. Our content development team tackled this challenge by devising a messaging strategy and matrix for each study, ensuring that the content created for the study materials matched the precision of the protocol. The team also simplified the complex information into easy-to-understand language to empower study participants with the necessary knowledge without feeling intimidated. This approach facilitated the team’s ability to make quick adjustments to the materials in response to multiple protocol amendments.

Clinical trial for bladder cancer patient recruitment content creation

SunRISe Clinical Trial Study branding and Content Development

Adding safeguards with version control and document management.

Like all studies, the SunRISe studies underwent protocol amendments over a two-year period. These changes necessitated significant updates to the study content. Our content and production teams implemented strict version controls and document management processes to facilitate easy tracking, review, and approval of revisions. Furthermore, investigators received updated materials that superseded previous versions, which they could discard with ease.

A phase 2 clinical trial evaluating TAR-200 in combination with cetrelimab for muscle-invasive bladder cancer.

Operationalizing the creative process to successfully deliver a large-scale clinical study.

Creating a brand identity system that could support multiple clinical studies.

Patient-friendly content development focused on health literacy.

Adding safeguards with version control and document management.

Learn how we can put our patient recruitment solutions to work for your next clinical trial.

Address

Contact

Connect